Blossom Health, a New York-based telepsychiatry startup founded in 2024 Raised $20 million in combined seed and Series A funding to expand an AI-powered platform that connects Psychiatrists with clinical pilots and automated administrative support. The round was led by Headline, where co-founder and managing partner Mathias Schilling joined the company’s board. Village Global and TA Ventures returned from previous rounds, with Operator Partners and Correlation Entities joining as new institutional backers, along with angel investors including the founders of General Catalyst, Flatiron Health, Sword Health and Zip.
Founded by CEO John Zhao, the company was built on a premise: the bottleneck in psychiatric treatment is not a lack of clinical knowledge, but a lack of time. In the United States, psychiatrists spend about half of their working hours on nonclinical tasks, including documentation, billing, insurance authorization, and scheduling. The Blossom platform does most of this by a A network of AI agents handles billing, admissions, care coordination, and medical writing, while a separate set of clinical copilots assists with symptom assessment, diagnosis clarification, and medication selection during patient encounters.
The scale of the problem
The psychiatric workforce shortage in the United States is severe and worsening. According to the Health Resources and Services Administration, more than 122 million Americans live in federally designated mental health professional shortage areas. The national psychiatrist-to-population ratio is one provider for every 5,058 residents. About 60 percent of practicing psychiatrists are 55 or older, meaning a significant portion of the current workforce will retire within the next decade. Waiting times for an initial psychiatric appointment range from three weeks to six months, depending on location, and many rural areas do not have a psychiatrist at all.
This gap created a market. US digital health startups will raise $14.2 billion in 2025, the highest amount since 2022. Companies powered by artificial intelligence make up 54 percent of that finance. Talkiatry, an online telepsychiatry platform specifically within mental health, raised $210 million in February 2026. Spring Health, which uses artificial intelligence for personalized treatment recommendations, is valued at $3.3 billion. Ambient clinical scribes, a category of artificial intelligence that automatically generates notes from patient conversations, generated $600 million in revenue last year alone.
💜 of EU technology
The latest rumblings from the EU tech scene, a story from our wise founder Boris and some questionable AI art. Free in your inbox every week. Register now!
It is small compared to the flower. The company says its tools are used by hundreds of clinicians across the US, treating more than 10,000 patients. Most patients are seen within 48 hours, many with same-day appointments. Blossom accepts all major commercial insurers, including Optum UnitedHealthcare, Aetna, Cigna Evernorth and Blue Cross Blue Shield, with an average copay of around $22.
A copilot, not a substitute
The “Copilot” framework is thoughtful and important. Blossom is not building a therapy chatbot. Its AI tools sit alongside licensed psychiatrists during clinical encounters, providing relevant information, helping assess symptoms against diagnostic criteria, and suggesting medication adjustments based on a patient’s history and current presentation. The psychiatrist retains clinical authority over each decision.
Between appointments, the platform uses artificial intelligence agents to connect with patients through text-based checks on sleep, mood, medication adherence and other metrics. Fortune reported that in the case of postpartum depression, for example, the system monitors spoken prompts for warning signs and prepares information for clinicians before the next visit. This approach transforms traditional episodic care, where a patient meets with a psychiatrist for 15 minutes every few months and is otherwise unsupported, into something closer to continuous monitoring.
Clinical claims are compelling, but early. Blossom said it has demonstrated the ability to stabilize mental health conditions and prevent progression to more intensive therapy, but the company has not published peer-reviewed clinical evidence. A data set of 10,000 patients makes sense for a company so young but too small to draw population-level conclusions about clinical efficacy.
A cerebral cautionary tale
Any startup operating at the intersection of artificial intelligence, telepsychiatry, and controlled substance inherits. reputational burden of those that came before. Cerebral, a telemental health company that raised $300 million in a $4.8 billion valuation in 2022, became the subject of a Justice Department investigation into controlled substance prescribing and paid $7 million to the Federal Trade Commission over allegations of misleading cancellation policies and data sharing. The company’s rapid growth, which prioritized patient volume over clinical rigor, damaged trust across the sector.
Blossom’s architecture is significantly different. It works through licensed psychiatrists, not independent prescribing nurses, and is positioned as an AI tool. decision support rather than decision makers. But the underlying tension remains: the scale of psychiatric care through technology requires maintenance clinical quality in volume the traditional practice model was never designed to manage. An AI copilot should be good enough to really help clinicians without introducing errors that a time-consuming psychiatrist might not catch, especially in drug selection, where psychiatric pharmacology is highly complex and highly individualized.
The $20 million will fund expansion in additional US states, new insurance partnerships, clinician recruitment and continued research and development. For a company founded less than two years ago, treating more than 10,000 patients with in-network insurance is a remarkable operational achievement. Whether the clinical copilot significantly improves outcomes or simply accelerates delivery of the same quality of care is a question the next round of funding will have to answer.
